Download PDF
Semin Respir Crit Care Med 2013; 34(05): 560-567
DOI: 10.1055/s-0033-1355439
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Idiopathic Pulmonary Arterial Hypertension

Rogerio Souza
1   Department of Pulmonary, Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil
,
Carlos Jardim
1   Department of Pulmonary, Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil
,
Marc Humbert
2   University of South Paris - Kremlin-Bicetre, Paris, France
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2013 (online)

    Permissions and Reprints

Abstract

Idiopathic pulmonary arterial hypertension (IPAH), formerly called primary pulmonary hypertension, is a rare disease (incidence and prevalence rates of approximately one and six cases per million inhabitants, respectively) with different clinical phenotypes. A group of diverse conditions manifest pulmonary arterial hypertension (PAH) and share similar pathological and/or clinical findings with IPAH. By definition, IPAH is diagnosed only after alternative diagnoses have been ruled out. Extensive investigation is needed to determine if PAH is associated with thyroid diseases, infectious diseases, autoimmune conditions, exposure to certain drugs (particularly anorexigens), certain genetic mutations, and so on. The presence of genetic abnormalities and risk factors (such as specific drug exposures) reinforces the “multiple hit” concept for the development of pulmonary hypertension. Fortunately, within the past two decades, therapeutic options have become available for IPAH, resulting in improved survival and clinical outcomes. At least seven different compounds have been registered for PAH treatment. However, even with aggressive PAH-specific therapy, mortality rates remain high (∼40% at 5 years). Given the high mortality rates, the use of combinations of agents that work by different pathways has been advocated (either as “add-on” therapy or initial “up front” therapy). Further, new therapeutic agents and treatment strategies are on the near horizon, aiming to further improve survival from the remarkable progress already seen.

Keywords

idiopathic pulmonary arterial hypertension - pulmonary arterial hypertension - heritable PAH - epidemiology
 

  • References

  • 1 Souza R, Jardim C. Trends in pulmonary arterial hypertension. Eur Respir Rev 2009; 18 (111) 7-12
    CrossrefPubMedGoogle Scholar
  • 2 Humbert M. The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries. Eur Respir Rev 2012; 21 (123) 4-5
    CrossrefPubMedGoogle Scholar
  • 3 Simonneau G, Robbins IM, Beghetti M , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (61, Suppl): S43-S54
    CrossrefPubMedGoogle Scholar
  • 4 Galiè N, Hoeper MM, Humbert M , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
    CrossrefPubMedGoogle Scholar
  • 5 Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34 (4) 888-894
    CrossrefPubMedGoogle Scholar
  • 6 Badesch DB, Champion HC, Sanchez MA , et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S55-S66
    CrossrefPubMedGoogle Scholar
  • 7 Cogan JD, Pauciulo MW, Batchman AP , et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174 (5) 590-598
    CrossrefPubMedGoogle Scholar
  • 8 Thomson JR, Machado RD, Pauciulo MW , et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37 (10) 741-745
    CrossrefPubMedGoogle Scholar
  • 9 Machado RD, Eickelberg O, Elliott CG , et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S32-S42
    CrossrefPubMedGoogle Scholar
  • 10 Sztrymf B, Coulet F, Girerd B , et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177 (12) 1377-1383
    CrossrefPubMedGoogle Scholar
  • 11 Germain M, Eyries M, Montani D , et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet 2013; 45 (5) 518-521
    CrossrefPubMedGoogle Scholar
  • 12 Girerd B, Montani D, Coulet F , et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181 (8) 851-861
    CrossrefPubMedGoogle Scholar
  • 13 Girerd B, Montani D, Eyries M , et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010; 11: 73
    CrossrefPubMedGoogle Scholar
  • 14 Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27 (2-3) 160-171
    PubMedGoogle Scholar
  • 15 Souza R, Humbert M, Sztrymf B , et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31 (2) 343-348
    CrossrefPubMedGoogle Scholar
  • 16 Walker AM, Langleben D, Korelitz JJ , et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 2006; 152 (3) 521-526
    CrossrefPubMedGoogle Scholar
  • 17 Boutet K, Frachon I, Jobic Y , et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009; 33 (3) 684-688
    CrossrefPubMedGoogle Scholar
  • 18 Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, Leroyer C. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE 2010; 5 (4) e10128
    CrossrefPubMedGoogle Scholar
  • 19 Savale L, Chaumais MC, Cottin V , et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40 (5) 1164-1172
    CrossrefPubMedGoogle Scholar
  • 20 Montani D, Bergot E, Günther S , et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125 (17) 2128-2137
    CrossrefPubMedGoogle Scholar
  • 21 Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005; 111 (5) 534-538
    CrossrefPubMedGoogle Scholar
  • 22 Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012; 122 (12) 4306-4313
    CrossrefPubMedGoogle Scholar
  • 23 Firth AL, Mandel J, Yuan JX. Idiopathic pulmonary arterial hypertension. Dis Model Mech 2010; 3 (5–6) 268-273
    CrossrefPubMedGoogle Scholar
  • 24 Giaid A, Yanagisawa M, Langleben D , et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328 (24) 1732-1739
    CrossrefPubMedGoogle Scholar
  • 25 Montani D, Souza R, Binkert C , et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest 2007; 131 (1) 101-108
    CrossrefPubMedGoogle Scholar
  • 26 Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 1991; 114 (6) 464-469
    CrossrefPubMedGoogle Scholar
  • 27 Michelakis ED. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 2003; 8 (1) 5-21
    CrossrefPubMedGoogle Scholar
  • 28 Yuan JX, Aldinger AM, Juhaszova M , et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98 (14) 1400-1406
    CrossrefPubMedGoogle Scholar
  • 29 Price LC, Wort SJ, Perros F , et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141 (1) 210-221
    CrossrefPubMedGoogle Scholar
  • 30 Humbert M, Souza R, Galiè N, McLaughlin V, Simonneau G, Rubin L. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev 2012; 21 (126) 267-270
    CrossrefPubMedGoogle Scholar
  • 31 Rich S, Dantzker DR, Ayres SM , et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107 (2) 216-223
    CrossrefPubMedGoogle Scholar
  • 32 D'Alonzo GE, Barst RJ, Ayres SM , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (5) 343-349
    CrossrefPubMedGoogle Scholar
  • 33 Humbert M, Sitbon O, Chaouat A , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (9) 1023-1030
    CrossrefPubMedGoogle Scholar
  • 34 Humbert M, Sitbon O, Chaouat A , et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (2) 156-163
    CrossrefPubMedGoogle Scholar
  • 35 Humbert M, Sitbon O, Yaïci A , et al; French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36 (3) 549-555
    CrossrefPubMedGoogle Scholar
  • 36 Badesch DB, Raskob GE, Elliott CG , et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137 (2) 376-387
    CrossrefPubMedGoogle Scholar
  • 37 Benza RL, Miller DP, Gomberg-Maitland M , et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (2) 164-172
    CrossrefPubMedGoogle Scholar
  • 38 Ling Y, Johnson MK, Kiely DG , et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186 (8) 790-796
    CrossrefPubMedGoogle Scholar
  • 39 Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J 2012; 40 (3) 604-611
    CrossrefPubMedGoogle Scholar
  • 40 Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41 (1) 217-223
    CrossrefPubMedGoogle Scholar
  • 41 Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21 (126) 313-320
    CrossrefPubMedGoogle Scholar
  • 42 Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol 2005; 43 (3) 143-147
    CrossrefPubMedGoogle Scholar
  • 43 Sitbon O, Humbert M, Jaïs X , et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111 (23) 3105-3111
    CrossrefPubMedGoogle Scholar
  • 44 Barst RJ, Rubin LJ, Long WA , et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334 (5) 296-301
    CrossrefPubMedGoogle Scholar
  • 45 Rubin LJ, Mendoza J, Hood M , et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112 (7) 485-491
    CrossrefPubMedGoogle Scholar
  • 46 Barst RJ, Gibbs JS, Ghofrani HA , et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S78-S84
    CrossrefPubMedGoogle Scholar
  • 47 Olschewski H, Simonneau G, Galiè N , et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5) 322-329
    CrossrefPubMedGoogle Scholar
  • 48 Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80 (2) 151-155
    PubMedGoogle Scholar
  • 49 Simonneau G, Barst RJ, Galie N , et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (6) 800-804
    CrossrefPubMedGoogle Scholar
  • 50 Tapson VF, Gomberg-Maitland M, McLaughlin VV , et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129 (3) 683-688
    CrossrefPubMedGoogle Scholar
  • 51 Tapson VF, Torres F, Kermeen F , et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142 (6) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 52 Jing ZC, Parikh K, Pulido T , et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127 (5) 624-633
    CrossrefPubMedGoogle Scholar
  • 53 Rubin LJ, Badesch DB, Barst RJ , et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12) 896-903
    CrossrefPubMedGoogle Scholar
  • 54 Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30 (2) 338-344
    CrossrefPubMedGoogle Scholar
  • 55 Galiè N, Olschewski H, Oudiz RJ , et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23) 3010-3019
    CrossrefPubMedGoogle Scholar
  • 56 McGoon MD, Frost AE, Oudiz RJ , et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135 (1) 122-129
    CrossrefPubMedGoogle Scholar
  • 57 Rubin L, Pulido T, Channick R , et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): Results from the SERAPHIN trial. [Abstract]. Chest 2012; 142 (4) 1026A
    CrossrefPubMedGoogle Scholar
  • 58 Galiè N, Ghofrani HA, Torbicki A , et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20) 2148-2157
    CrossrefPubMedGoogle Scholar
  • 59 Galiè N, Brundage BH, Ghofrani HA , et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119 (22) 2894-2903
    CrossrefPubMedGoogle Scholar
  • 60 Jing ZC, Yu ZX, Shen JY , et al; Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183 (12) 1723-1729
    CrossrefPubMedGoogle Scholar
  • 61 Ghofrani HA, Voswinckel R, Gall H , et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6 (2) 155-166
    CrossrefPubMedGoogle Scholar
  • 62 Ghofrani HA, Hoeper MM, Halank M , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36 (4) 792-799
    CrossrefPubMedGoogle Scholar
  • 63 Ghofrani H, Galie N, Grimminger F , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1). [Abstract]. Chest 2012; 142 (4) 1027A DOI: 10.1378/chest.1462799.
    CrossrefPubMedGoogle Scholar
  • 64 Ghofrani H, Grimminger F, Hoeper M , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double-blind, placebo-controlled study (CHEST-1). [Abstract]. Chest 2012; 142 (4) 1023A
    CrossrefPubMedGoogle Scholar
  • 65 McLaughlin VV, Benza RL, Rubin LJ , et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55 (18) 1915-1922
    CrossrefPubMedGoogle Scholar
  • 66 Simonneau G, Rubin LJ, Galiè N , et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149 (8) 521-530
    CrossrefPubMedGoogle Scholar
  • 67 Humbert M, Barst RJ, Robbins IM , et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24 (3) 353-359
    CrossrefPubMedGoogle Scholar
  • 68 Kemp K, Savale L, O'Callaghan DS , et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012; 31 (2) 150-158
    CrossrefPubMedGoogle Scholar
  • 69 Souza R, Jardim C, Martins B , et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin 2005; 21 (6) 907-911
    CrossrefPubMedGoogle Scholar
  • 70 Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30 (4) 394-403
    PubMedGoogle Scholar
  • 71 dos Santos Fernandes CJ, Jardim CV, Hovnanian A , et al. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010; 56 (9) 715-720
    CrossrefPubMedGoogle Scholar
  • 72 Sitbon O, McLaughlin VV, Badesch DB , et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60 (12) 1025-1030
    CrossrefPubMedGoogle Scholar
  • 73 O'Callaghan DS, Humbert M. A critical analysis of survival in pulmonary arterial hypertension. Eur Respir Rev 2012; 21 (125) 218-222
    CrossrefPubMedGoogle Scholar